PW Medtech Group Co. Ltd. has announced its unaudited interim financial results for the six months ended June 30, 2025. The company reported a revenue of approximately RMB414.4 million, marking a 22.4% increase from the RMB338.4 million recorded in the corresponding period of 2024. The revenue growth was observed across various business segments, including the Infusion Set Business and Blood Purification Business. No specific details regarding net income, profit, or loss were disclosed in the announcement. Additionally, there was no mention of earnings per share in the results. The financial highlights reflect the company's continued growth and expansion in its core business areas.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.